View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 8, 2022

Akston doses first volunteers in Phase II/III Covid-19 vaccine trial

Assessing the safety, tolerability and humoral immunogenicity profile of the vaccine at day 56 is the study’s primary objective.

Akston Biosciences has dosed the first volunteers in a Phase II/III clinical trial of its low cost, shelf-stable, thermostable protein subunit Covid-19 vaccine, AKS-452, in India. 

India’s Central Drugs Standard Control Organization (CDSCO) granted approval for the trial, which was initiated by Veeda Clinical Research in the Indian city of Ahmedabad.

The double-blind, placebo-controlled, multicentre trial intends to enrol 1,500 healthy volunteers aged 18 and above, who will be given two 90µg doses of the vaccine at a gap of 28 days or placebo. 

The two-dose regimen comprises a first dose including AKS-452 plus adjuvant that boosts the immune response of the body and the second dose with only AKS-452. 

Assessing the safety, tolerability and humoral immunogenicity profile of the vaccine at day 56 following a two-dose series in a combined bridging and a Phase II/III trial is the primary objective.

Dosing is expected to conclude by 15 April and interim data is anticipated to be available in June this year. 

On obtaining the trial results, Akston plans to submit these data for seeking Emergency Use Authorization (EUA).

Akston currently has an AKS-452 licencing, manufacturing and marketing agreement in place with Biolexis, a Strides Group subsidiary. 

As per the deal, Biolexis will produce and market the vaccine under the brand name AmbiVax-C in India and more than 130 countries.

Akston Biosciences president and CEO Todd Zion said: “This clinical trial represents an important step in the development of protein-based Covid-19 vaccines. 

“We are working closely with Strides Group, which will manufacture AKS-452 at scale so that it can be quickly rolled out after receiving an EUA.” 

The latest development comes after the company announced plans to start a Phase II trial of AKS-452 as a booster in the Netherlands.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy